Last reviewed · How we verify

NCT05518513

Continuous Infusion and Intermittent Bolus Adductor Canal Block for Total Knee Arthroplasty

Recruiting now NA Last updated 5 April 2024
What this trial tests

NA trial testing Bupivacain in Arthroplasty, Replacement, Knee in 66 participants. Currently enrolling.

Timeline
1 November 2022
Primary endpoint
30 June 2024
30 September 2024

Quick facts

Lead sponsorNational Cheng-Kung University Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment66
Start date1 November 2022
Primary completion30 June 2024
Estimated completion30 September 2024
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Cheng-Kung University Hospital

Who can join

20 and older, any sex, with Arthroplasty, Replacement, Knee or Adductor Canal Block. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators believed the analgesic efficacy of adductor canal block on patients receiving total knee arthroplasty. However, the analgesic effects of different delivery regimens and duration of effects are variable. The investigators hypothesize that using continuous infusion and shorter interval bolus of local anesthetics to perform adductor canal block will reduce pain scale and opioid consumption in patients receiving total knee arthroplasty compared with longer interval bolus of local anesthetics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Bupivacain

Trials testing the same drug.

Other recruiting trials for Arthroplasty, Replacement, Knee

Currently open trials in the same condition.

Other National Cheng-Kung University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05518513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing